Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Fixed high-dose antithymocyte globulin (ATLG, Grafalon®) is effective for induction in intermediate-risk kidney-transplant recipients (KTR) but adds cost and may predispose to infection. We examined whether titrating ATLG according to the absolute lymphocyte count (ALC) can safely reduce drug exposure while preserving early graft outcomes.
In a prospective, single-centre cohort (January 2024 – March 2025), 58 consecutive intermediate-risk KTR received an initial 3 mg kg⁻¹ ATLG on day 0. Subsequent doses were withheld once the mean ALC fell below 500 cells µL⁻¹. All patients received standard triple maintenance immunosuppression. Outcomes through 3 months—biopsy-proven acute rejection (BPAR) and clinically significant infection—were compared with a contemporaneous historical cohort of 27 KTR given a fixed 8 mg kg⁻¹ ATLG induction. Fisher’s exact test was used for categorical variables; P < 0.05 denoted significance.
Dynamic dosing yielded a mean cumulative ATLG exposure of 6.45 ± 1.53 mg kg⁻¹ (≈ 20 % less than the fixed 8 mg kg⁻¹ protocol), translating into a similar proportional saving in drug expenditure.
Infection: day 7, 7/58 (12.1 %) vs 6/27 (22.2 %) (risk ratio [RR] 0.55, P = 0.35); month 1, 4/58 (6.9 %) vs 3/27 (11.1 %) (RR 0.62, P = 0.68); no infections between months 1 and 3 in either cohort.
Rejection: day 7, 1/58 (1.7 %) vs 3/27 (11.1 %) (RR 0.16, P = 0.15); month 1, 3/58 (5.2 %) vs 2/27 (7.4 %) (RR 0.70, P = 1.00); no BPAR after month 1 in either group.
No graft losses or deaths occurred during follow-up.
ALC-guided ATLG induction reduced drug consumption by one-fifth without a statistically significant increase in early rejection or infection, suggesting that this simple bedside algorithm offers a cost-saving, patient-specific alternative to fixed high-dose protocols. Larger randomised trials with longer follow-up are warranted to confirm non-inferiority and evaluate long-term outcomes.
